Developer docs
API playgroundTry for free, no card

Search company profiles

ENCell

Full company profile

uuid0002u7g

Namestring
ENCell
Legal namestring
ENCell Co., Ltd.
Websiteurl
encellinc.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

ENCell Co., Ltd. (KOSDAQ: 456070) is a South Korea-based contract development and manufacturing organization (CDMO) founded in 2018 and headquartered in Seoul. The company provides Good Manufacturing Practice (GMP) manufacturing services for advanced therapy developers, with particular specialization in cell and gene therapy production. Its core offering includes clinical trial material manufacturing for NK cell therapies and gene therapies, exemplified by its contract manufacturing agreement with Ingenium Therapeutics for gengleucel—an FDA orphan drug-designated NK cell therapy candidate for acute myeloid leukemia—and its gene therapy-focused collaboration with US-based Andelyn Biosciences.

The company's technology platform centers on compliant, specialized manufacturing processes for living-cell products and regenerative therapies. ENCell has invested in capabilities spanning NK cell therapy production and advanced regenerative/stem cell-based applications, including anti-aging indications. Its partnership with Andelyn creates a 'dual hemisphere' manufacturing network linking facilities in the United States and Asia-Pacific, enabling clients to run parallel regional manufacturing for clinical trials and reducing cross-border regulatory and logistical friction.

ENCell generates revenue through B2B contract manufacturing agreements with biotech and pharmaceutical companies developing cell and gene therapies. Pricing is quote-based and not publicly disclosed, consistent with project-driven CDMO economics. The company targets a horizontal customer segment—biotech and pharma sponsors requiring GMP manufacturing for clinical-stage advanced therapies—and is beginning to extend into proprietary regenerative/anti-aging applications funded by its December 2025 capital raise of approximately KRW 22.5 billion (~USD 15.3 million), led by NH Investment & Securities.

Short descriptiontext

ENCell (KOSDAQ: 456070) is a South Korea-based GMP contract manufacturer specializing in cell and gene therapy production, including NK cell therapies, for biotech and pharmaceutical clients pursuing clinical development in the US and Asia-Pacific.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
cell therapy manufacturing, gene therapy CDMO, GMP contract manufacturing, regenerative therapy development, NK cell therapy production
Industry3 codes
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Biopharmaceutical CDMO
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeProfessional Services
Description

ENCell generates revenue through contract manufacturing agreements with biotech and pharmaceutical companies for production of clinical trial materials, cell therapies, and gene therapy products under GMP conditions.

koreabiomed.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ENCell is a contract development and manufacturing organization (CDMO) specializing in GMP (Good Manufacturing Practice) production of clinical trial materials for cell and gene therapy developers. The company manufactures clinical-stage cell therapies such as NK cell therapy candidates (including gengleucel for acute myeloid leukemia) and provides a strategic dual-hemisphere manufacturing network bridging the United States and Asia-Pacific regions through its partnership with Andelyn Biosciences.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Manufacturing partnership enables in-country manufacturing for local clinical trials and patient populations
Product and service4 records
1GMP Contract Manufacturing Services
CategoryContract Manufacturing (CDMO)
2NK Cell Therapy Manufacturing
CategoryCell Therapy Manufacturing
3Dual-Hemisphere Cell and Gene Therapy Manufacturing
CategoryContract Manufacturing (CDMO)
4Advanced Regenerative Therapy Development
CategoryRegenerative Medicine
Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-04
Description

ENCell signed a contract manufacturing agreement with Ingenium Therapeutics to produce clinical trial materials for gengleucel, an NK cell therapy candidate for acute myeloid leukemia, supporting U.S. clinical development. The therapy received FDA orphan drug designation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-21
Description

Andelyn Biosciences and ENCell signed a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific regions for gene therapy development. The partnership combines both companies' GMP manufacturing facilities, technical expertise, and regional networks to enable a streamlined 'dual hemisphere' workflow that reduces regulatory and logistical complexities of international expansion.

Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based cell and gene therapy CDMO with GMP manufacturing capabilities. Direct peer and strategic partner; ENCell's dual-hemisphere model is built around Andelyn's US facility as the North American counterpart to ENCell's APAC operations.

TypeBroad incumbent
Description

Korea's largest biopharmaceutical CDMO offering contract manufacturing for biologics and advanced therapies. As a domestic incumbent with significantly greater scale, Samsung Biologics competes for the same Korean and global cell/gene therapy contracts.

TypeBroad incumbent
Description

Korean-headquartered CDMO providing small-molecule API, biologics, and cell/gene therapy manufacturing services. Comparable end-market and geography; competes for advanced therapy manufacturing contracts in the APAC region.

TypeBroad incumbent
Description

Global leader in cell and gene therapy CDMO services with extensive GMP manufacturing capacity. Sets pricing benchmarks and capability expectations for advanced therapy CDMOs worldwide, including for NK cell therapy production.

TypeBroad incumbent
Description

Global CDMO offering cell and gene therapy manufacturing services alongside biologics. Competes for clinical-stage cell therapy manufacturing contracts and has comparable GMP capabilities to ENCell.

TypeBroad incumbent
Description

Cell and gene therapy CDMO unit of WuXi AppTec providing process development and GMP manufacturing. Significant scale and global footprint make it a direct competitor for advanced therapy manufacturing contracts.

TypeBroad incumbent
Description

Major global CDMO with cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Comparable service offerings for clinical-stage cell therapy developers.

TypeRegional player
Description

Korean biopharmaceutical company with manufacturing capabilities and growing presence in biosimilars and novel biologics. Comparable Korean-domiciled biomanufacturing competitor focused on domestic and select international markets.

9Vineti
TypeEmerging player
Description

Specialized technology and services provider for cell and gene therapy supply chain management. Adjacent peer in the cell therapy ecosystem with comparable focus on enabling clinical and commercial cell therapy workflows.

TypeEmerging player
Description

Cell therapy CDMO specializing in GMP manufacturing for clinical and commercial cell therapies including allogeneic platforms. Comparable scale and specialization to ENCell for cell therapy manufacturing.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ENCell

Biopharmaceutical CDMOencellinc.com

ENCell (KOSDAQ: 456070) is a South Korea-based GMP contract manufacturer specializing in cell and gene therapy production, including NK cell therapies, for biotech and pharmaceutical clients pursuing clinical development in the US and Asia-Pacific.

What ENCell does

ENCell Co., Ltd. (KOSDAQ: 456070) is a South Korea-based contract development and manufacturing organization (CDMO) founded in 2018 and headquartered in Seoul. The company provides Good Manufacturing Practice (GMP) manufacturing services for advanced therapy developers, with particular specialization in cell and gene therapy production. Its core offering includes clinical trial material manufacturing for NK cell therapies and gene therapies, exemplified by its contract manufacturing agreement with Ingenium Therapeutics for gengleucel—an FDA orphan drug-designated NK cell therapy candidate for acute myeloid leukemia—and its gene therapy-focused collaboration with US-based Andelyn Biosciences.

The company's technology platform centers on compliant, specialized manufacturing processes for living-cell products and regenerative therapies. ENCell has invested in capabilities spanning NK cell therapy production and advanced regenerative/stem cell-based applications, including anti-aging indications. Its partnership with Andelyn creates a 'dual hemisphere' manufacturing network linking facilities in the United States and Asia-Pacific, enabling clients to run parallel regional manufacturing for clinical trials and reducing cross-border regulatory and logistical friction.

ENCell generates revenue through B2B contract manufacturing agreements with biotech and pharmaceutical companies developing cell and gene therapies. Pricing is quote-based and not publicly disclosed, consistent with project-driven CDMO economics. The company targets a horizontal customer segment—biotech and pharma sponsors requiring GMP manufacturing for clinical-stage advanced therapies—and is beginning to extend into proprietary regenerative/anti-aging applications funded by its December 2025 capital raise of approximately KRW 22.5 billion (~USD 15.3 million), led by NH Investment & Securities.

ENCell firmographics

Firmographics
Name
ENCell
Legal name
ENCell Co., Ltd.
Website
https://encellinc.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
ENCell (KOSDAQ: 456070) is a South Korea-based GMP contract manufacturer specializing in cell and gene therapy production, including NK cell therapies, for biotech and pharmaceutical clients pursuing clinical development in the US and Asia-Pacific.
Ownership category
akta.pro rank

ENCell industry classification

Industry
Product category
Biopharmaceutical CDMO
NAICS
Pharmaceutical and Medicine Manufacturing (32541)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAGABAE
Gene Therapy (Viral Vector/Plasmid) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Cell therapy manufacturing
  • Gene therapy CDMO
  • GMP contract manufacturing
  • Regenerative therapy development
  • NK cell therapy production

Where ENCell is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Markets served

ENCell business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services: ENCell generates revenue through contract manufacturing agreements with biotech and pharmaceutical companies for production of clinical trial materials, cell therapies, and gene therapy products under GMP conditions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

ENCell product offering

Product offering

Core offering

ENCell is a contract development and manufacturing organization (CDMO) specializing in GMP (Good Manufacturing Practice) production of clinical trial materials for cell and gene therapy developers. The company manufactures clinical-stage cell therapies such as NK cell therapy candidates (including gengleucel for acute myeloid leukemia) and provides a strategic dual-hemisphere manufacturing network bridging the United States and Asia-Pacific regions through its partnership with Andelyn Biosciences.

Differentiator

Problem solved

Functional benefit

Products and services

  • GMP Contract Manufacturing Services
  • NK Cell Therapy Manufacturing
  • Dual-Hemisphere Cell and Gene Therapy Manufacturing
  • Advanced Regenerative Therapy Development

Quantifiable outcome

  • Manufacturing partnership enables in-country manufacturing for local clinical trials and patient populations

Companies that use ENCell

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

ENCell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

ENCell partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Ingenium TherapeuticscoreStrategic or Co-development Partner · 4 June 2026ENCell signed a contract manufacturing agreement with Ingenium Therapeutics to produce clinical trial materials for gengleucel, an NK cell therapy candidate for acute myeloid leukemia, supporting U.S. clinical development. The therapy received FDA orphan drug designation.
  • Andelyn BiosciencescoreStrategic or Co-development Partner · 21 April 2026Andelyn Biosciences and ENCell signed a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific regions for gene therapy development. The partnership combines both companies' GMP manufacturing facilities, technical expertise, and regional networks to enable a streamlined 'dual hemisphere' workflow that reduces regulatory and logistical complexities of international expansion.

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

ENCell competitors and assessment

Company assessment

Direct peers

  • Andelyn Biosciences: US-based cell and gene therapy CDMO with GMP manufacturing capabilities. Direct peer and strategic partner; ENCell's dual-hemisphere model is built around Andelyn's US facility as the North American counterpart to ENCell's APAC operations.

Broad incumbents

  • Samsung Biologics: Korea's largest biopharmaceutical CDMO offering contract manufacturing for biologics and advanced therapies. As a domestic incumbent with significantly greater scale, Samsung Biologics competes for the same Korean and global cell/gene therapy contracts.
  • SK Pharmteco: Korean-headquartered CDMO providing small-molecule API, biologics, and cell/gene therapy manufacturing services. Comparable end-market and geography; competes for advanced therapy manufacturing contracts in the APAC region.
  • Lonza: Global leader in cell and gene therapy CDMO services with extensive GMP manufacturing capacity. Sets pricing benchmarks and capability expectations for advanced therapy CDMOs worldwide, including for NK cell therapy production.
  • AGC Biologics: Global CDMO offering cell and gene therapy manufacturing services alongside biologics. Competes for clinical-stage cell therapy manufacturing contracts and has comparable GMP capabilities to ENCell.
  • WuXi Advanced Therapies: Cell and gene therapy CDMO unit of WuXi AppTec providing process development and GMP manufacturing. Significant scale and global footprint make it a direct competitor for advanced therapy manufacturing contracts.
  • Catalent: Major global CDMO with cell and gene therapy capabilities including viral vector and cell therapy manufacturing. Comparable service offerings for clinical-stage cell therapy developers.

Regional players

  • Celltrion: Korean biopharmaceutical company with manufacturing capabilities and growing presence in biosimilars and novel biologics. Comparable Korean-domiciled biomanufacturing competitor focused on domestic and select international markets.

Emerging players

  • Vineti: Specialized technology and services provider for cell and gene therapy supply chain management. Adjacent peer in the cell therapy ecosystem with comparable focus on enabling clinical and commercial cell therapy workflows.
  • RoslinCT: Cell therapy CDMO specializing in GMP manufacturing for clinical and commercial cell therapies including allogeneic platforms. Comparable scale and specialization to ENCell for cell therapy manufacturing.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

ENCell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ENCell leadership team

Management profile

Number of profiles

ENCell funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ENCell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENCell

What does ENCell do?

ENCell is a contract development and manufacturing organization (CDMO) specializing in GMP (Good Manufacturing Practice) production of clinical trial materials for cell and gene therapy developers. The company manufactures clinical-stage cell therapies such as NK cell therapy candidates (including gengleucel for acute myeloid leukemia) and provides a strategic dual-hemisphere manufacturing network bridging the United States and Asia-Pacific regions through its partnership with Andelyn Biosciences.

Is ENCell a public or private company?

ENCell is a private company. It is classified as public and is currently operating.

When was ENCell founded?

ENCell was founded in 2018. It employs 11 to 50 people.

Where is ENCell based?

ENCell is headquartered in Seoul, South Korea, in the Asia region.

How does ENCell make money?

One revenue line is on record: contract Manufacturing Services.

Who are ENCell's main competitors?

Andelyn Biosciences is listed as a direct peer. Broad incumbents are Samsung Biologics, SK Pharmteco, Lonza, AGC Biologics, WuXi Advanced Therapies and Catalent. Celltrion is listed as a regional player. Emerging players are Vineti and RoslinCT.

Does ENCell have an API?

No public API is recorded for ENCell.

What industry is ENCell in?

ENCell's product category is Biopharmaceutical CDMO. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 32541 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireCharcot Marie Tooth Disease - Drug Pipeline Insights and Competitive Landscape, 2026 | 15+ Drugs Signal Gene Therapy and Neuromuscular Innovation OpportunitiesResearchAndMarkets published a report on the Charcot-Marie-Tooth disease pipeline, covering 13+ companies and 15+ investigational therapies. It highlights Ignaseclant (NMD PHARMA) in Phase II and EN001 (ENCell) in Phase I, with other candidates including EDK060 and ELP-0. The report assesses development phases, routes, and molecule types.Neurology livePreclinical Study Suggests Stem Cell Therapy EN001 and Insulin May Improve Symptoms of Charcot-Marie-Tooth Disease Type 1AA preclinical study presented at the 2025 PNS meeting found that EN001 and insulin improved muscle strength, endurance, and remyelination in CMT1A models, with combination therapy enhancing benefits. The study was the first to report insulin as a potential therapeutic for CMT1A. ENCell's EN001 received FDA orphan drug designation in March 2025.CGTLiveAround the Helix: Cell and Gene Therapy Company Updates – April 22, 2026The article reports on recent updates and developments in the cell and gene therapy sectors, including research, collaborations, and clinical trials. Notable topics include progress in therapies for SMA, neuroblastoma, Duchenne muscular dystrophy, and OPMD, as well as a new manufacturing partnership between Andelyn Biosciences and ENCell Co.KBRENCell wins US clinical manufacturing contract for Ingenium’s NK cell therapyENCell signed a contract manufacturing agreement with Ingenium Therapeutics to produce clinical trial materials for gengleucel, an NK cell therapy candidate for acute myeloid leukemia, supporting U.S. clinical development. The therapy has received FDA orphan drug designation and is planned to advance directly into a Phase 2 trial following positive feedback from a pre-IND meeting. Ingenium recently licensed gengleucel to Lipior Bio for up to 235 billion won ($153 million) for development and commercialization in China and Japan, highlighting the therapy's commercial potential.KBRENCell, Andelyn Biosciences partner to build global gene therapy production networkENCell and Andelyn Biosciences have signed a partnership agreement to expand gene therapy development and manufacturing globally, focusing on accelerating drug development programs and supply chain establishment in the Asia-Pacific region.PR NewswireAndelyn Biosciences and ENCell Co., Ltd Announce Strategic Partnership to Expand Global Reach of Gene Therapy ManufacturingAndelyn Biosciences and ENCell Co., Ltd. signed a Collaboration Agreement to establish a strategic manufacturing bridge between the United States and Asia-Pacific regions for gene therapy development. The partnership combines both companies' GMP manufacturing facilities, technical expertise, and regional networks to enable a streamlined 'dual hemisphere' workflow that reduces regulatory and logistical complexities of international expansion. The collaboration aims to accelerate the path to commercialization for gene therapies by facilitating in-country manufacturing for local clinical trials and patient populations.KBRENCell wins FDA orphan drug designation for EN001 in Duchenne muscular dystrophyENCell, a biotech company listed on Kosdaq, announced that the U.S. FDA granted Orphan Drug Designation to its cell therapy candidate, EN001, for Duchenne muscular dystrophy. This is the second ODD for EN001, indicating its potential in treating rare neuromuscular diseases and supporting ENCell's strategy to expand its application to broader indications.ChosunbizENCell secures FDA orphan status for stem cell therapy targeting DMDENCell announced that its allogeneic umbilical cord-derived mesenchymal stem cell therapy candidate EN001 received orphan drug designation from the U.S. FDA for Duchenne muscular dystrophy, a fatal pediatric rare disease caused by dystrophin gene deficiency. This marks the second orphan designation for EN001, following one for Charcot-Marie-Tooth disease, positioning it as a platform therapy for rare neuromuscular diseases. The designation provides benefits including seven years of market exclusivity post-approval, tax credits for clinical expenses, and expedited review, which the company plans to leverage for global technology transfer and clinical acceleration.KBRENCell seeks EMA orphan drug status for CMT therapyENCell has submitted an application to the European Medicines Agency seeking Orphan Drug Designation for its Charcot-Marie-Tooth disease treatment candidate EN001, building on the FDA ODD it received for the same indication in February last year. EN001 is an allogeneic mesenchymal stem cell therapy derived from umbilical cord tissue, currently undergoing domestic clinical trials for CMT1A. The company plans to explore partnering and technology-transfer opportunities with global pharmaceutical companies as development progresses.KBRENCell and Japan's CRC sign strategic partnership for cell and gene therapy expansionENCell has signed a strategic partnership agreement with Cell Resources Corporation (CRC), a subsidiary of Japan's Alfresa Group, to expand its cell and gene therapy business in Japan. The deal involves CRC introducing ENCell's EN001 therapy to Japanese pharmaceutical firms for licensing opportunities while ENCell provides consulting and technology transfer services to support CRC's operations.